| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $51,925,014 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01EY012085 | Intercellular Communication in the Eye Lens | 000 | 28 | NIH | 12/10/2025 | $453,947 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01GM128731 | Structure and Function of the Essential Cell Cycle Regulator Cdc34 | 000 | 9 | NIH | 2/12/2026 | $319,302 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK138035 | Paracrine effects of leptin in regulating visceral fat expansion | 000 | 3 | NIH | 2/25/2026 | $387,500 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 002 | 32 | NIH | 2/2/2026 | -$51,484 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 000 | 32 | NIH | 12/18/2025 | $505,540 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 000 | 32 | NIH | 12/18/2025 | $51,484 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 001 | 32 | NIH | 1/15/2026 | $51,484 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK143234 | Metabolite Markers of Diabetic Kidney Disease | 000 | 1 | NIH | 4/17/2026 | $825,255 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK144299 | Role of OxPLs-mediated oxidative damage in MASH | 000 | 1 | NIH | 5/5/2026 | $639,990 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK133304 | A novel pathway controls liver injury in NASH | 000 | 5 | NIH | 2/27/2026 | $521,908 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK133463 | Cellular mechanisms of NLRP3 activation by ALCAT1 in diet-induced obesity | 000 | 4 | NIH | 3/9/2026 | $528,581 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK135179 | Mechanisms and therapeutic potential of blocking the mitochondrial Mg2+ channel Mrs2 in obesity and NAFLD | 000 | 4 | NIH | 12/30/2025 | $524,931 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK128247 | The Regulation of Hepatic Metabolic Zonation by the Diabetes Gene TCF7L2 | 000 | 5 | NIH | 12/18/2025 | $489,396 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK129676 | Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizers | 000 | 5 | NIH | 3/23/2026 | $682,149 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DE031352 | Evaluation of the Role of Macrophage Migratory Inhibitory Factor (MIF) in mediating Stem Cell Analgesia in a Model of Orofacial Pain | 001 | 4 | NIH | 4/16/2026 | $46,384 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DE031352 | Evaluation of the Role of Macrophage Migratory Inhibitory Factor (MIF) in mediating Stem Cell Analgesia in a Model of Orofacial Pain | 000 | 4 | NIH | 1/14/2026 | $417,454 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DE033455 | TRPM2-mediated immune activation initiates radiation-induced loss of oral function | 000 | 2 | NIH | 3/27/2026 | $622,744 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK107680 | Ketones, Muscle Metabolism, and SGLT2 Inhibitors | 001 | 10 | NIH | 4/1/2026 | $647,334 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DK097554 | Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes | 000 | 13 | NIH | 3/24/2026 | $684,914 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DE017102 | TRPC1, Calcium, and Saliva Secretion | 000 | 21 | NIH | 3/30/2026 | $530,652 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA293672 | Developing purinergic receptor inverse agonists for treating triple negative breast cancer | 000 | 2 | NIH | 3/5/2026 | $567,600 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA299621 | Development of first-in-class AAK1 PROTACs for ovarian cancer | 000 | 1 | NIH | 3/25/2026 | $593,338 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA293655 | Structure and function of RAD51 paralog tumor suppressor complexes in genome maintenance | 000 | 3 | NIH | 4/27/2026 | $640,241 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA300241 | Targeting mucin-type O-glycosylation for EGFR mutant non-small cell lung cancer | 000 | 1 | NIH | 3/27/2026 | $609,846 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DA058018 | Gabapentinoid/opioid mixtures: abuse and toxicity | 001 | 4 | NIH | 2/6/2026 | $42,727 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01DA058018 | Gabapentinoid/opioid mixtures: abuse and toxicity | 000 | 4 | NIH | 1/30/2026 | $384,558 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA269866 | Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma | 001 | 4 | NIH | 4/16/2026 | $47,950 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA269866 | Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma | 000 | 4 | NIH | 1/9/2026 | $431,562 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA281726 | Novel mechanism of chemokine nitration in bladder cancer | 000 | 3 | NIH | 4/24/2026 | $389,933 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA279696 | The role and mechanism of RNA m6A modification in the pathogenesis and drug-resistance of prostate cancer | 000 | 4 | NIH | 4/10/2026 | $374,561 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA279971 | Biomarkers For BRCA1-Deficient Cancers | 000 | 3 | NIH | 5/5/2026 | $436,807 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA262757 | Enhancing endoplasmic reticulum stress in ovarian cancer | 000 | 5 | NIH | 3/5/2026 | $527,072 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R01CA244261 | Mechanistic characterization of the cell cycle-dependent DNA repair pathway- Resubmission | 000 | 7 | NIH | 2/27/2026 | $332,169 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | UG3AG090675 | Building Unique Infrastructure for Large-scale Dementia research in French-Speaking Africa (BUILD-FSA) Project | 002 | 2 | NIH | 3/25/2026 | $274,600 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | UG3AG090675 | Building Unique Infrastructure for Large-scale Dementia research in French-Speaking Africa (BUILD-FSA) Project | 001 | 2 | NIH | 3/9/2026 | $22,954 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | UG3AG090675 | Building Unique Infrastructure for Large-scale Dementia research in French-Speaking Africa (BUILD-FSA) Project | 000 | 2 | NIH | 3/4/2026 | $206,588 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | U01AI182210 | An oral vaccine against Chlamydia trachomatis | 000 | 3 | NIH | 4/3/2026 | $2,150,524 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | U01CA283749 | The role of tumor-macrophage hybrid cells in prostate cancer metastasis | 001 | 3 | NIH | 4/29/2026 | $8,575 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | U01CA283749 | The role of tumor-macrophage hybrid cells in prostate cancer metastasis | 000 | 3 | NIH | 4/21/2026 | $628,593 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | S10OD040222 | Illumina NovaSeq X Sequencing System | 000 | 1 | NIH | 5/7/2026 | $750,000 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | T32AG021890 | Training Grant on the Biology of Aging | 000 | 21 | NIH | 5/5/2026 | $502,894 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R37AI136697 | Biochemistry of SAMHD1-mediated innate immunity responses | 000 | 7 | NIH | 4/27/2026 | $555,306 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R37CA249305 | The role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLC | 000 | 7 | NIH | 3/4/2026 | $375,936 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM156189 | Dissecting the DNA Damage Response with Functional Proteomics | 000 | 2 | NIH | 1/14/2026 | $354,375 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM156189 | Dissecting the DNA Damage Response with Functional Proteomics | 001 | 2 | NIH | 3/11/2026 | $39,375 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM163544 | Spatiotemporal regulation of DNA metabolism pathways | 000 | 1 | NIH | 5/7/2026 | $433,125 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM163922 | Protein Intrinsic Disorder in Genome Regulation | 000 | 1 | NIH | 4/8/2026 | $378,000 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM153228 | Mechanisms of enhancer dynamics and assembly in gene regulation | 000 | 3 | NIH | 4/27/2026 | $387,508 |
| | 2026 | 2026 | THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | 7703 FLOYD CURL DR | SAN ANTONIO | TX | 78229-3901 | BEXAR | USA | R35GM137798 | Deciphering the chromatin-based DNA damage response pathway | 001 | 7 | NIH | 4/9/2026 | $433,125 |
|
